Old Web
English
Sign In
Acemap
>
authorDetail
>
Keiko Suzaki
Keiko Suzaki
Boehringer Ingelheim
Medicine
Internal medicine
Placebo
Type 2 diabetes
Empagliflozin
4
Papers
59
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (1)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium-glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes.
2021
BMJ Open
Daisuke Yabe
Kosuke Shiki
Keiko Suzaki
Thomas Meinicke
Yutaro Kotobuki
Kenichiro Nishida
Douglas Clark
Atsutaka Yasui
Yutaka Seino
Show All
Source
Cite
Save
Citations (1)
1